Bupivacaine

Generic Name: Bupivacaine

Brand Names: Exparel, Kenalog, Marbeta, Marcaine, Marcaine With Epinephrine, Marvona Suik, P-Care M, P-Care MG, P-care, Posimir, Readysharp Anesthetics Plus Ketorolac, Readysharp-A, Readysharp-p40, Readysharp-p80, Sensorcaine, Sensorcaine With Epinephrine, Vivacaine, Xaracoll, Exparel liposomal

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₈N_₂O

CAS Number: 38396-39-3

Unique Ingredient Identifier: Y8335394RO

Background: Bupivacaine is a widely used local anesthetic agent.

Indication: As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.

Bupivacaine, in liposome suspension, is indicated in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia. In adults, it is also indicated as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.

Bupivacaine, in combination with meloxicam, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Bupivacaine, alone or in combination with epinephrine, is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Finally, its use is not indicated in all blocks given clinically significant risks associated with use.

Associated Conditions: Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Hemolytic Anemia, Hypercalcemia caused by Cancer, Keloids Scars, Leukemias, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Ocular Inflammation, Ophthalmia, Sympathetic, Osteoarthritis (OA), Pain, Labor, Polymyositis, Postoperative pain, Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute Bursitis, Acute Idiopathic Nephrotic Syndrome, Acute Lupus Erythematosus, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute nonspecific tenosynovitis, Cystic tumors of aponeurosis, Cystic tumors of tendon, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Inflammatory lesions of granuloma annulare, Inflammatory lesions of lichen planus, Inflammatory lesions of lichen simplex, Non-suppurative Thyroiditis, Permphigus, Severe Allergic Reactions

Associated Therapies: General Anesthesia, Local Anaesthesia therapy, Regional nerve block therapy

Clinical Trials

Dose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair

Phase 2

Completed

Conditions: Postoperative Pain

Interventions: Drug: SKY0402
Drug: Bupivacaine HCl

First Posted Date: 2007-06-13

Last Posted Date: 2021-03-02

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 98

Registration Number: NCT00485433

Locations: 🇺🇸
Saddleback Valley Outpatient Surgery, Laguna Hills, California, United States
🇺🇸
Kirby Outpatient Surgical Center, Houston, Texas, United States
🇺🇸
Arcadia Methodist Hospital, Arcadia, California, United States

and more 4 locations

Phase 1 Thorough QT Study in Young Healthy Volunteers

Phase 1

Completed

Conditions: Postoperative Pain

Interventions: Drug: SKY0402
Drug: Moxifloxacin 400mg
Drug: Placebo injection
Drug: Placebo tablet

First Posted Date: 2007-06-13

Last Posted Date: 2021-02-16

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 48

Registration Number: NCT00485667

Locations: 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom

Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty

Phase 2

Completed

Conditions: Postoperative Pain

Interventions: Drug: SKY0402
Drug: Bupivacaine HCl

First Posted Date: 2007-06-13

Last Posted Date: 2022-06-28

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 138

Registration Number: NCT00485693

Locations: 🇺🇸
West Alabama Research, Inc., Birmingham, Alabama, United States
🇺🇸
California Clinical Research, Inc., Davis, California, United States
🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States

and more 6 locations

Efficacy and Cost: Benefit Ratio of 0, 1, and 2 Medial Branch Blocks for Lumbar Facet Joint Radiofrequency Denervation

Not Applicable

Completed

Conditions: Low Back Pain

Interventions: Procedure: Radiofrequency denervation of medial branches
Drug: 0.5% bupivacaine
Drug: 2% lidocaine
Procedure: Radiofrequency denervation

First Posted Date: 2007-06-08

Last Posted Date: 2011-07-26

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 151

Registration Number: NCT00484159

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, D.C., District of Columbia, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States